Generalized Anxiety Disorder
Conditions
Keywords
Generalized anxiety disorder, CBD, Metered dose inhaler
Brief summary
The goal of this clinical trial is to learn if inhaled drug NC-107 works to treat Generalized anxiety disorder in adults. It will also learn about the safety of the drug NC-107. The main questions it aims to answer are: Does the inhaled drug NC-107 decrease the severity of anxiety in participants? What medical problems could participants have when taking drug NC-107? How quickly does NC-107 absorb and get into the blood stream? Researchers will compare drug NC-107 to a placebo (a look-alike substance that contains no drug) to see how effective NC-107 in treating generalized anxiety disorder. Participants will be equal to or above 18 years of age and sign an informed consent. They will answer two questionnaires about anxiety and have vitals taken, as well as blood drawn for laboratory results. If a questionnaire reveals moderate anxiety and all blood work is normal the patient will enter the study. The patient will be instructed on the use of an inhaler, that will deliver the medication via the lung. Two puffs twice daily of NC-107 or placebo will be used during the remainder of the study. Blood will be drawn for peak and trough levels of NC-107. Questionnaires will be completed at each visit.
Interventions
DRUGMeasure concentrations of CBD in spot urine collections from subjects treated with inhaled CBD
Measure concentrations of CBD in spot urine collections from subjects with generalized anxiety disorder treated with inhaled CBD
DRUGDetermine the presence and concentration of CBD in subject's plasma with inhaled CBD
Determine the presence and concentration of CBD in plasma of subjects with generalized anxiety disorder treated with inhaled CBD
Sponsors
Nutraceutical Corporation
Trinity Hypertension & Metabolic Research Institute
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Intervention model description
Double blinded Parallel Study
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
Inclusion Criteria: Subjects must satisfy all the following criteria to be included in the study 1. Capable of reading, comprehending the consent process and providing written informed consent to participate in the study. 2. Male or female ≥ 18 years of age with generalized anxiety disorder. This includes a STAI ≥16 (moderate anxiety) or a GAD-7 score ≥10 (moderate anxiety). 3. Stable pharmacotherapeutics regimen with no change in the past 3 months. 4. Cannabis Naïve or abstinent from regular use (defined as \>1x/month) for more than 6 months prior to the baseline visit. 5. Negative urine screen for metabolites of THC. 6. Women may be enrolled if all three of the following criteria are met: * Have a negative urine pregnancy test at screening, for females of childbearing potential. * Are not breastfeeding * Do not plan to become pregnant during the study And if one of the following three criteria is met * Have had a hysterectomy or tubal ligation at least 6 months prior to signing the informed consent form * Have been postmenopausal for at least 1 year * Are of childbearing potential and will practice one of the following methods of birth control throughout the study: oral, patch, injectable, or implantable hormone contraception, intrauterine device, diaphragm plus spermicide or female condom plus spermicide.
Exclusion criteria
1. Patients with severe hypertension (mean seated cuff diastolic blood pressure \>115 mmHg or mean seated systolic blood pressure \>180mmHg) or any form of secondary hypertension at time of screening 2. Patients within the past 6 months with a history of hypertensive encephalopathy, stroke, or transient ischemic attack. 3. Patients within the last 6 months with a history of myocardial infarction, percutaneous transluminal coronary revascularization, coronary bypass graft, valvular surgery or unstable angina. 4. Patients with a history of heart block greater than First Degree Sinoatrial Block. Wolff-Parkinson-White Syndrome, Sick Sinus Syndrome, Atrial Fibrillation, Atrial Flutter, Congestive Heart Failure, or other manifestations of clinically significant cardiac valvular disease. 5. Patients with hemo-dynamically significant cardiac valvular disease. 6. Patients with evidence of significant chronic renal impairment as indicated by a serum creatinine of \> 2.5mg/dL at Screening. 7. Patients with evidence of liver disease as indicated by AST (SGOT) or ALT (SGPT) \> 2.5 times or total bilirubin \> 1.5 times, the upper limit of the laboratory normal range at Screening. 8. Patients who demonstrate other laboratory test values deviating from the normal range which are considered clinically significant by the investigator. 9. Patients with insulin and non-insulin dependent diabetes mellitus not controlled on diet, insulin or oral hypoglycemics as defined by a HgA1c \>10.5 mg/dcL at Visit 1 10. Severe psychological or emotional condition ( Current substance abuse, major depressive, psychotic, and bipolar disorder) that are not associated with Generalized Anxiety Disorder which may interfere with participation in the study. 11. History of or current use of illicit drugs or alcohol abuse. 12. Participation in a clinical trial and taking any investigational drug within 30 days prior to enrolling into the study (Screening). 13. Any other medical condition which, in the Investigator's opinion, may render the patient unable to complete the study or which would interfere with optimal participation in the study or produce significant risk to the patient \-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Measure the concentration of CBD in the plasma of subjects | 4 weeks | Measure the concentration of CBD in the plasma of male and female subjects with Generalized Anxiety Disorder treated with inhaled CBD. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Concentrations of CBD in spot urine collections. | 4 weeks | Measure concentrations of CBD in spot urine collections from male and female subjects with Generalized Anxiety Disorder treated with inhaled CBD. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Decrease in the levels of Anxiety with Questionnaires | 4 weeks | Whether there is a decrease in the levels of anxiety in the STAI and or GAD-7 questionnaires at weeks 1, 2, 3, and 4, when compared to baseline week 0. |
Countries
United States
Contacts
Primary ContactHenry A Punzi, MD, FCP, FASH
Outcome results
None listed